Member Info for Laura2022

What a great day

From a few people today

Grainger, cobalt etc

Strange

Porky

Wonder what he thinks as he thought GDR could be 50p

He prefers these types of directors

Just released now on gdr

 

genedrive plc (AIM: GDR), the point of care Pharmacogenetic testing company, announces that on 4 January 2024, Cytox Limited, a company which Dr. Ian Gilham, the Company's Non-Executive Chairman, was previously a Director of, appointed a liquidator in connection with a creditors voluntary winding up.  No notice of administrators' proposal has yet been filed although the business was estimated to have a deficiency as regards creditors of £257,405.

PYC next

Under the terms of the new agreement, ValiRx will benefit from Physiomics' experience in modelling the effects of prostate cancer treatment, as well the use of the latest version of its Virtual Tumour™ technology, which will be applied to derive valuable information from the additional data generated by the completed clinical trial of VAL201. Physiomics will also support ValiRx in modelling the use of the VAL201 peptide in endometriosis (VAL301) and Coronavirus (BC201).

Physiomics has developed a quantitative systems pharmacology approach that uses pre-clinical and clinical data to model the activity of a drug candidate. This data can be used to explore the mechanism of action, disease impact and optimal dosing strategies.

Physiomics will receive a fee (capped at £6m) of 6% of any future net revenues that may be received by ValiRx relating to its commercialisation of VAL201 and its derivatives in any indication, including prostate cancer, endometriosis and treatment for Coronavirus infection.

Brave enough to short ?

Doubt it ....

Under the terms of the new agreement, ValiRx will benefit from Physiomics' experience in modelling the effects of prostate cancer treatment, as well the use of the latest version of its Virtual Tumour™ technology, which will be applied to derive valuable information from the additional data generated by the completed clinical trial of VAL201. Physiomics will also support ValiRx in modelling the use of the VAL201 peptide in endometriosis (VAL301) and Coronavirus (BC201).

Physiomics has developed a quantitative systems pharmacology approach that uses pre-clinical and clinical data to model the activity of a drug candidate. This data can be used to explore the mechanism of action, disease impact and optimal dosing strategies.

Physiomics will receive a fee (capped at £6m) of 6% of any future net revenues that may be received by ValiRx relating to its commercialisation of VAL201 and its derivatives in any indication, including prostate cancer, endometriosis and treatment for Coronavirus infection.

And with £6mln to PYC too

All good for both PM2022

Grainger/porky silent

VAL up 50%

We did suggest the EUDA $100mln was linked to VAL update

Will he apologise for his lies now ?

GB

Pyc benefits too from VAL201

Up to £6mln

It's so funny

PYC and VAL

201 due very soon in the next few weeks. The signs seemed very positive.

Val excellent presentations today

Thanks

See they've just has news too...will take a look over there

Absolutely NU

I'm all ears

Appreciate your willingness to strike a deal

Finally